Avacta Group Regulatory News (AVCT)

25 January 2016

Avacta Group plc

("Avacta" or "the Group" or "the Company")

Result of Annual General Meeting

Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, announces that at the Annual General Meeting held earlier today, all resolutions were duly passed.

Following approval of the resolution relating to the consolidation of 1 new ordinary share of 10p each for every 100 existing ordinary shares of 0.1p each, every 100 existing ordinary shares of 0.1p each will be consolidated into 1 new ordinary share of 10p each.

The share consolidation is expected to become effective at 8.00am on 26 January 2016.

Enquiries:

Notes to Editors

Avacta Group plc (www.avacta.com)

Avacta's principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.

Antibodies dominate markets worth in excess of $50bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.

Avacta has a pre-clinical biotech development programme with an in-house focus on oncology and bleeding disorders as well as several partnered development programmes. Avacta is commercialising Affimer reagents through custom Affimer services to provide bespoke solutions to customers and via a growing on-line catalogue of Affimer reagents.